Alcohol Use Disorder Market Report and Forecast 2025-2034
Description
The alcohol use disorder market was valued at USD 843.45 Million in 2024, driven by the increasing prevalence of alcohol use across the 8 major markets. The market is expected to grow at a CAGR of 6.20% during the forecast period of2025-2034, with the values likely to reach USD 1539.23 Million by 2034.
Alcohol Use Disorder Market Overview
Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It ranges from mild to severe and can include symptoms like cravings, withdrawal, and a high tolerance for alcohol.
Alcohol Use Disorder Market Growth Drivers
Growing Awareness and Emphasis on Public Health to Boost Market Growth
Rising public awareness about alcohol misuse and increasing health campaigns are key drivers of the alcohol use disorder (AUD) market. For instance, in June 2024, the World Health Organization (WHO) released a global status report on alcohol and substance use disorders, revealing that 2.6 million deaths annually are attributed to alcohol consumption, with men disproportionately affected. This report underscores the urgent need for comprehensive interventions, which is expected to drive the development of effective treatments and strategies. As the spotlight on AUD grows, demand for innovative therapies and services is projected to fuel market growth during the forecast period.
Advent of New Therapies to Meet Rising Alcohol Use Disorder Market Demand
The growing demand for novel therapeutic approaches and the integration of psychological therapies into AUD treatment are driving innovation in the market. For instance, in August 2024, in a landmark phase III trial, the UK’s National Health Service (NHS) will be investigating ketamine-assisted therapy for preventing alcohol relapse, combining low-dose ketamine infusions with psychological support. Covering 280 adults across multiple NHS sites, this trial is aimed at establishing a groundbreaking treatment model. If successful, the introduction of ketamine-assisted therapy could revolutionise AUD treatment, expand therapeutic portfolios, and significantly drive market development by meeting the unmet needs of severe AUD patients during the forecast period.
Alcohol Use Disorder Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Increasing Prevalence of Telehealth Interventions
The market is seeing a notable trend toward the integration of telehealth services. This shift facilitates remote diagnosis, consultation, and treatment management, broadening access for patients unable to attend in-person therapy sessions. The convenience and confidentiality offered by telehealth are significantly enhancing patient engagement and continuous care, thereby contributing to market growth. For instance, in March 2024, a study revealed that telehealth could be a more effective approach to treating alcoholism compared to traditional in-person therapy sessions. The research found that individuals undergoing alcohol use disorder treatment via telehealth were more likely to attend therapy sessions consistently and adhere to prescribed anti-alcohol medications for a longer duration than those receiving treatment in person.
Expansion of Medication-Assisted Treatment Options
There is a growing expansion in medication-assisted treatments (MAT) for alcohol use disorder, with newer pharmacological agents being approved and developed. This trend is driven by the increasing need for effective long-term management strategies for AUD. Medications such as naltrexone, acamprosate, and the newer nalmefene are proving critical in helping reduce alcohol dependence symptoms, thereby boosting the market's value by providing varied options tailored to individual needs.
Rising Awareness and Government Initiatives
Increasing public health campaigns and government initiatives aimed at reducing alcohol dependency are significant trends in the AUD market. These programs promote awareness about alcohol misuse and support rehabilitation services, contributing to early diagnosis and treatment. This proactive approach helps mitigate the long-term consequences of alcohol use disorder on public health systems and stimulates market development.
Integration of Behavioral Therapy in Treatment Protocols
There is a growing emphasis on incorporating behavioral therapies alongside pharmacological treatments in managing alcohol use disorder. Techniques such as Cognitive Behavioral Therapy (CBT) and motivational interviewing are becoming integral parts of comprehensive treatment plans. This integration addresses both the psychological and physical aspects of AUD, enhancing treatment efficacy and ultimately supporting the market’s diversification and depth.
Alcohol Use Disorder Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disorder Type
Market Segmentation Based on Disorder Type to Witness Growth
The market share is dominated by the alcohol dependence segment, attributed to the higher prevalence of alcohol dependence compared to other types of disorders, such as alcohol abuse or addiction. Alcohol dependence is often characterized by a strong physical desire to consume alcohol, which leads to significant healthcare needs and treatment services. This segment's growth is driven by increasing recognition of alcohol dependence as a medical condition that requires comprehensive treatment strategies, including medication, counseling, and support services, fueling the demand for effective solutions.
Alcohol Use Disorder Market Analysis by Region
The United States leads the regional market share, primarily due to its high prevalence of alcohol use disorder, significant healthcare spending, and robust access to treatment options. The U.S. market benefits from a strong presence of major pharmaceutical companies actively developing treatments, coupled with widespread awareness and a solid healthcare infrastructure supporting early diagnosis and intervention. This region also sees substantial investment in research and development, promoting innovations in therapy and drug development to tackle alcohol dependency effectively.
Leading Players in the Alcohol Use Disorder Market
The key features of the market report comprise clinical trials analysis, patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Alkermes
Alkermes plc is a biopharmaceutical company headquartered in Dublin, Ireland, established in 1987. Alkermes offers Vivitrol, a once-monthly injectable formulation of naltrexone that helps prevent relapse in patients after they have detoxified. This product is part of a broader portfolio focusing on central nervous system disorders.
BioCorRx, Inc.
BioCorRx, Inc. is a U.S.-based healthcare solutions company founded in 2008, headquartered in Anaheim, California. BioCorRx is known for its BioCorRx Recovery Program, a comprehensive treatment solution for alcohol and opioid addiction, which includes counselling and medication-assisted treatment featuring naltrexone implants.
Ethypharm
Ethypharm is a pharmaceutical company headquartered in Saint-Cloud, France, founded in 1977. Ethypharm provides Selincro, an oral medication containing nalmefene designed to reduce alcohol consumption in adults with alcohol dependence who have a high drinking risk level, without physical withdrawal symptoms and who do not require immediate detoxification. This product forms a part of Ethypharm's broader portfolio, which includes a focus on addiction treatment alongside other therapeutic areas.
INDIVIOR
INDIVIOR is a pharmaceutical company based in Slough, UK, established in 1994. INDIVIOR offers products like Sublocade and Subutex, which are primarily aimed at opioid dependence but also have applications in treating alcohol use disorder through comprehensive medication-assisted treatment strategies, focusing on both physical and psychological aspects of addiction.
Other key players in the market include Omeros Corporation, Kinnov Therapeutics, and Adial Pharmaceuticals.
Key Questions Answered in the Alcohol Use Disorder Market
Alcohol Use Disorder Market Overview
Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It ranges from mild to severe and can include symptoms like cravings, withdrawal, and a high tolerance for alcohol.
Alcohol Use Disorder Market Growth Drivers
Growing Awareness and Emphasis on Public Health to Boost Market Growth
Rising public awareness about alcohol misuse and increasing health campaigns are key drivers of the alcohol use disorder (AUD) market. For instance, in June 2024, the World Health Organization (WHO) released a global status report on alcohol and substance use disorders, revealing that 2.6 million deaths annually are attributed to alcohol consumption, with men disproportionately affected. This report underscores the urgent need for comprehensive interventions, which is expected to drive the development of effective treatments and strategies. As the spotlight on AUD grows, demand for innovative therapies and services is projected to fuel market growth during the forecast period.
Advent of New Therapies to Meet Rising Alcohol Use Disorder Market Demand
The growing demand for novel therapeutic approaches and the integration of psychological therapies into AUD treatment are driving innovation in the market. For instance, in August 2024, in a landmark phase III trial, the UK’s National Health Service (NHS) will be investigating ketamine-assisted therapy for preventing alcohol relapse, combining low-dose ketamine infusions with psychological support. Covering 280 adults across multiple NHS sites, this trial is aimed at establishing a groundbreaking treatment model. If successful, the introduction of ketamine-assisted therapy could revolutionise AUD treatment, expand therapeutic portfolios, and significantly drive market development by meeting the unmet needs of severe AUD patients during the forecast period.
Alcohol Use Disorder Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Increasing Prevalence of Telehealth Interventions
The market is seeing a notable trend toward the integration of telehealth services. This shift facilitates remote diagnosis, consultation, and treatment management, broadening access for patients unable to attend in-person therapy sessions. The convenience and confidentiality offered by telehealth are significantly enhancing patient engagement and continuous care, thereby contributing to market growth. For instance, in March 2024, a study revealed that telehealth could be a more effective approach to treating alcoholism compared to traditional in-person therapy sessions. The research found that individuals undergoing alcohol use disorder treatment via telehealth were more likely to attend therapy sessions consistently and adhere to prescribed anti-alcohol medications for a longer duration than those receiving treatment in person.
Expansion of Medication-Assisted Treatment Options
There is a growing expansion in medication-assisted treatments (MAT) for alcohol use disorder, with newer pharmacological agents being approved and developed. This trend is driven by the increasing need for effective long-term management strategies for AUD. Medications such as naltrexone, acamprosate, and the newer nalmefene are proving critical in helping reduce alcohol dependence symptoms, thereby boosting the market's value by providing varied options tailored to individual needs.
Rising Awareness and Government Initiatives
Increasing public health campaigns and government initiatives aimed at reducing alcohol dependency are significant trends in the AUD market. These programs promote awareness about alcohol misuse and support rehabilitation services, contributing to early diagnosis and treatment. This proactive approach helps mitigate the long-term consequences of alcohol use disorder on public health systems and stimulates market development.
Integration of Behavioral Therapy in Treatment Protocols
There is a growing emphasis on incorporating behavioral therapies alongside pharmacological treatments in managing alcohol use disorder. Techniques such as Cognitive Behavioral Therapy (CBT) and motivational interviewing are becoming integral parts of comprehensive treatment plans. This integration addresses both the psychological and physical aspects of AUD, enhancing treatment efficacy and ultimately supporting the market’s diversification and depth.
Alcohol Use Disorder Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disorder Type
- Alcohol Abuse
- Alcohol Dependence
- Alcohol Addiction
- Others
- Medication
- Therapy
- Multidisciplinary
- Others
- Hospitals
- De-Addiction and Rehabilitation Centres
- Others
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Market Segmentation Based on Disorder Type to Witness Growth
The market share is dominated by the alcohol dependence segment, attributed to the higher prevalence of alcohol dependence compared to other types of disorders, such as alcohol abuse or addiction. Alcohol dependence is often characterized by a strong physical desire to consume alcohol, which leads to significant healthcare needs and treatment services. This segment's growth is driven by increasing recognition of alcohol dependence as a medical condition that requires comprehensive treatment strategies, including medication, counseling, and support services, fueling the demand for effective solutions.
Alcohol Use Disorder Market Analysis by Region
The United States leads the regional market share, primarily due to its high prevalence of alcohol use disorder, significant healthcare spending, and robust access to treatment options. The U.S. market benefits from a strong presence of major pharmaceutical companies actively developing treatments, coupled with widespread awareness and a solid healthcare infrastructure supporting early diagnosis and intervention. This region also sees substantial investment in research and development, promoting innovations in therapy and drug development to tackle alcohol dependency effectively.
Leading Players in the Alcohol Use Disorder Market
The key features of the market report comprise clinical trials analysis, patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Alkermes
Alkermes plc is a biopharmaceutical company headquartered in Dublin, Ireland, established in 1987. Alkermes offers Vivitrol, a once-monthly injectable formulation of naltrexone that helps prevent relapse in patients after they have detoxified. This product is part of a broader portfolio focusing on central nervous system disorders.
BioCorRx, Inc.
BioCorRx, Inc. is a U.S.-based healthcare solutions company founded in 2008, headquartered in Anaheim, California. BioCorRx is known for its BioCorRx Recovery Program, a comprehensive treatment solution for alcohol and opioid addiction, which includes counselling and medication-assisted treatment featuring naltrexone implants.
Ethypharm
Ethypharm is a pharmaceutical company headquartered in Saint-Cloud, France, founded in 1977. Ethypharm provides Selincro, an oral medication containing nalmefene designed to reduce alcohol consumption in adults with alcohol dependence who have a high drinking risk level, without physical withdrawal symptoms and who do not require immediate detoxification. This product forms a part of Ethypharm's broader portfolio, which includes a focus on addiction treatment alongside other therapeutic areas.
INDIVIOR
INDIVIOR is a pharmaceutical company based in Slough, UK, established in 1994. INDIVIOR offers products like Sublocade and Subutex, which are primarily aimed at opioid dependence but also have applications in treating alcohol use disorder through comprehensive medication-assisted treatment strategies, focusing on both physical and psychological aspects of addiction.
Other key players in the market include Omeros Corporation, Kinnov Therapeutics, and Adial Pharmaceuticals.
Key Questions Answered in the Alcohol Use Disorder Market
- What was the alcohol use disorder market value in 2024?
- What is the alcohol use disorder market forecast outlook for 2025-2034?
- What is the market breakup based on the disorder type?
- What is the market breakup based on the treatment type?
- What is the market breakup based on the end user?
- What are the major factors aiding the alcohol use disorder market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major alcohol use disorder market trends?
- Which disorder type will lead the market segment?
- Which treatment type will lead the market segment?
- Which end user will lead the market segment?
- Who are the key players involved in the alcohol use disorder market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Alcohol Use Disorder Market Overview – 8 Major Markets
- 3.1 Alcohol Use Disorder Market Historical Value (2018-2024)
- 3.2 Alcohol Use Disorder Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Alcohol Use Disorder Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Alcohol Use Disorder Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.2 Prevalence, by Country
- 7.2.1 United States
- 7.2.2 United Kingdom
- 7.2.3 Germany
- 7.2.4 France
- 7.2.5 Italy
- 7.2.6 Spain
- 7.2.7 India
- 7.2.8 Japan
- 7.3 Diagnosed Cases, by Country
- 7.3.1 United States
- 7.3.2 United Kingdom
- 7.3.3 Germany
- 7.3.4 France
- 7.3.5 Italy
- 7.3.6 Spain
- 7.3.7 India
- 7.3.8 Japan
- 7.4 Treatment Seeking Rate, by Country
- 7.4.1 United States
- 7.4.2 United Kingdom
- 7.4.3 Germany
- 7.4.4 France
- 7.4.5 Italy
- 7.4.6 Spain
- 7.4.7 India
- 7.4.8 Japan
- 8 Alcohol Use Disorder Market Landscape – 8 Major Markets
- 8.1 Alcohol Use Disorder Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Alcohol Use Disorder Market: Product Landscape
- 8.2.1 Analysis by Treatment Type
- 8.2.2 Analysis by Disorder Type
- 9 Alcohol Use Disorder Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Alcohol Use Disorder Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Alcohol Use Disorder Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Alcohol Use Disorder Market (2018-2034) by Disorder Type
- 12.1.1 Market Overview
- 12.1.2 Alcohol Abuse
- 12.1.3 Alcohol Dependence
- 12.1.4 Alcohol Addiction
- 12.1.5 Others
- 12.2 Alcohol Use Disorder Market (2018-2034) by Treatment Type
- 12.2.1 Market Overview
- 12.2.2 Medication
- 12.2.3 Therapy
- 12.2.4 Multidisciplinary
- 12.2.5 Others
- 12.3 Alcohol Use Disorder Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals
- 12.3.3 De-Addiction & Rehabilitation Centers
- 12.3.4 Others
- 12.4 Alcohol Use Disorder Market (2018-2034) by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 United Kingdom
- 12.4.4 Germany
- 12.4.5 France
- 12.4.6 Italy
- 12.4.7 Spain
- 12.4.8 Japan
- 12.4.9 India
- 13 United States Alcohol Use Disorder Market (218-2034)
- 13.1 United States Alcohol Use Disorder Market (2018-2034) by Disorder Type
- 13.1.1 Market Overview
- 13.1.2 Alcohol Abuse
- 13.1.3 Alcohol Dependence
- 13.1.4 Alcohol Addiction
- 13.1.5 Others
- 13.2 United States Alcohol Use Disorder Market (2018-2034) by Treatment Type
- 13.2.1 Market Overview
- 13.2.2 Medication
- 13.2.3 Therapy
- 13.2.4 Multidisciplinary
- 13.2.5 Others
- 13.3 United States Alcohol Use Disorder Market (2018-2034) by End User
- 13.3.1 Market Overview
- 13.3.2 Hospitals
- 13.3.3 De-Addiction & Rehabilitation Centers
- 13.3.4 Others
- 14 United Kingdom Alcohol Use Disorder Market (218-2034)
- 14.1 United Kingdom Alcohol Use Disorder Market (2018-2034) by Disorder Type
- 14.1.1 Market Overview
- 14.1.2 Alcohol Abuse
- 14.1.3 Alcohol Dependence
- 14.1.4 Alcohol Addiction
- 14.1.5 Others
- 14.2 United Kingdom Alcohol Use Disorder Market (2018-2034) by Treatment Type
- 14.2.1 Market Overview
- 14.2.2 Medication
- 14.2.3 Therapy
- 14.2.4 Multidisciplinary
- 14.2.5 Others
- 14.3 United Kingdom Alcohol Use Disorder Market (2018-2034) by End User
- 14.3.1 Market Overview
- 14.3.2 Hospitals
- 14.3.3 De-Addiction & Rehabilitation Centers
- 14.3.4 Others
- 15 Germany Alcohol Use Disorder Market (218-2034)
- 15.1 Germany Alcohol Use Disorder Market (2018-2034) by Disorder Type
- 15.1.1 Market Overview
- 15.1.2 Alcohol Abuse
- 15.1.3 Alcohol Dependence
- 15.1.4 Alcohol Addiction
- 15.1.5 Others
- 15.2 Germany Alcohol Use Disorder Market (2018-2034) by Treatment Type
- 15.2.1 Market Overview
- 15.2.2 Medication
- 15.2.3 Therapy
- 15.2.4 Multidisciplinary
- 15.2.5 Others
- 15.3 Germany Alcohol Use Disorder Market (2018-2034) by End User
- 15.3.1 Market Overview
- 15.3.2 Hospitals
- 15.3.3 De-Addiction & Rehabilitation Centers
- 15.3.4 Others
- 16 France Alcohol Use Disorder Market (218-2034)
- 16.1 France Alcohol Use Disorder Market (2018-2034) by Disorder Type
- 16.1.1 Market Overview
- 16.1.2 Alcohol Abuse
- 16.1.3 Alcohol Dependence
- 16.1.4 Alcohol Addiction
- 16.1.5 Others
- 16.2 France Alcohol Use Disorder Market (2018-2034) by Treatment Type
- 16.2.1 Market Overview
- 16.2.2 Medication
- 16.2.3 Therapy
- 16.2.4 Multidisciplinary
- 16.2.5 Others
- 16.3 France Alcohol Use Disorder Market (2018-2034) by End User
- 16.3.1 Market Overview
- 16.3.2 Hospitals
- 16.3.3 De-Addiction & Rehabilitation Centers
- 16.3.4 Others
- 17 Italy Alcohol Use Disorder Market (218-2034)
- 17.1 Italy Alcohol Use Disorder Market (2018-2034) by Disorder Type
- 17.1.1 Market Overview
- 17.1.2 Alcohol Abuse
- 17.1.3 Alcohol Dependence
- 17.1.4 Alcohol Addiction
- 17.1.5 Others
- 17.2 Italy Alcohol Use Disorder Market (2018-2034) by Treatment Type
- 17.2.1 Market Overview
- 17.2.2 Medication
- 17.2.3 Therapy
- 17.2.4 Multidisciplinary
- 17.2.5 Others
- 17.3 Italy Alcohol Use Disorder Market (2018-2034) by End User
- 17.3.1 Market Overview
- 17.3.2 Hospitals
- 17.3.3 De-Addiction & Rehabilitation Centers
- 17.3.4 Others
- 18 Spain Alcohol Use Disorder Market (218-2034)
- 18.1 Spain Alcohol Use Disorder Market (2018-2034) by Disorder Type
- 18.1.1 Market Overview
- 18.1.2 Alcohol Abuse
- 18.1.3 Alcohol Dependence
- 18.1.4 Alcohol Addiction
- 18.1.5 Others
- 18.2 Spain Alcohol Use Disorder Market (2018-2034) by Treatment Type
- 18.2.1 Market Overview
- 18.2.2 Medication
- 18.2.3 Therapy
- 18.2.4 Multidisciplinary
- 18.2.5 Others
- 18.3 Spain Alcohol Use Disorder Market (2018-2034) by End User
- 18.3.1 Market Overview
- 18.3.2 Hospitals
- 18.3.3 De-Addiction & Rehabilitation Centers
- 18.3.4 Others
- 19 Japan Alcohol Use Disorder Market (218-2034)
- 19.1 Japan Alcohol Use Disorder Market (2018-2034) by Disorder Type
- 19.1.1 Market Overview
- 19.1.2 Alcohol Abuse
- 19.1.3 Alcohol Dependence
- 19.1.4 Alcohol Addiction
- 19.1.5 Others
- 19.2 Japan Alcohol Use Disorder Market (2018-2034) by Treatment Type
- 19.2.1 Market Overview
- 19.2.2 Medication
- 19.2.3 Therapy
- 19.2.4 Multidisciplinary
- 19.2.5 Others
- 19.3 Japan Alcohol Use Disorder Market (2018-2034) by End User
- 19.3.1 Market Overview
- 19.3.2 Hospitals
- 19.3.3 De-Addiction & Rehabilitation Centers
- 19.3.4 Others
- 20 India Alcohol Use Disorder Market (218-2034)
- 20.1 India Alcohol Use Disorder Market (2018-2034) by Disorder Type
- 20.1.1 Market Overview
- 20.1.2 Alcohol Abuse
- 20.1.3 Alcohol Dependence
- 20.1.4 Alcohol Addiction
- 20.1.5 Others
- 20.2 India Alcohol Use Disorder Market (2018-2034) by Treatment Type
- 20.2.1 Market Overview
- 20.2.2 Medication
- 20.2.3 Therapy
- 20.2.4 Multidisciplinary
- 20.2.5 Others
- 20.3 India Alcohol Use Disorder Market (2018-2034) by End User
- 20.3.1 Market Overview
- 20.3.2 Hospitals
- 20.3.3 De-Addiction & Rehabilitation Centers
- 20.3.4 Others
- 21 Regulatory Framework
- 21.1 Regulatory Overview
- 21.2 US FDA
- 21.3 EU EMA
- 21.4 Japan PMDA
- 21.5 India CDSCO
- 21.6 Others
- 22 Patent Analysis
- 22.1 Analysis by Type of Patent
- 22.2 Analysis by Publication Year
- 22.3 Analysis by Issuing Authority
- 22.4 Analysis by Patent Age
- 22.5 Analysis by CPC Analysis
- 22.6 Analysis by Patent Valuation
- 23 Clinical Trials Analysis
- 23.1 Analysis by Trial Registration Year
- 23.2 Analysis by Trial Status
- 23.3 Analysis by Trial Phase
- 23.4 Analysis by Therapeutic Area
- 23.5 Analysis by Geography
- 24 Grants Analysis
- 24.1 Analysis by Year
- 24.2 Analysis by Amount Awarded
- 24.3 Analysis by Issuing Authority
- 24.4 Analysis by Grant Application
- 24.5 Analysis by Funding Institute
- 24.6 Analysis by NIH Departments
- 24.7 Analysis by Recipient Organization
- 25 Funding and Investment Analysis
- 25.1 Analysis by Funding Instances
- 25.2 Analysis by Drug Class of Funding
- 25.3 Analysis by Funding Amount
- 25.4 Analysis by Leading Players
- 25.5 Analysis by Leading Investors
- 25.6 Analysis by Geography
- 26 Strategic Initiatives
- 26.1 Analysis by Partnership Instances
- 26.2 Analysis by Drug Class of Partnership
- 26.3 Analysis by Leading Players
- 26.4 Analysis by Geography
- 27 Supplier Landscape
- 27.1 Market Share Analysis, By Region (Top 5 Companies)
- 27.2 BioCorRx, Inc.
- 27.2.1 Financial Analysis
- 27.2.2 Product Portfolio
- 27.2.3 Demographic Reach and Achievements
- 27.2.4 Companies News and Developments
- 27.2.5 Certifications
- 27.3 Ethypharm
- 27.3.1 Financial Analysis
- 27.3.2 Product Portfolio
- 27.3.3 Demographic Reach and Achievements
- 27.3.4 Companies News and Developments
- 27.3.5 Certifications
- 27.4 INDIVIOR
- 27.4.1 Financial Analysis
- 27.4.2 Product Portfolio
- 27.4.3 Demographic Reach and Achievements
- 27.4.4 Companies News and Developments
- 27.4.5 Certifications
- 27.5 Omeros Corporation
- 27.5.1 Financial Analysis
- 27.5.2 Product Portfolio
- 27.5.3 Demographic Reach and Achievements
- 27.5.4 Companies News and Developments
- 27.5.5 Certifications
- 27.6 Kinnov Therapeutics
- 27.6.1 Financial Analysis
- 27.6.2 Product Portfolio
- 27.6.3 Demographic Reach and Achievements
- 27.6.4 Companies News and Developments
- 27.6.5 Certifications
- 27.7 Adial Pharmaceuticals
- 27.7.1 Financial Analysis
- 27.7.2 Product Portfolio
- 27.7.3 Demographic Reach and Achievements
- 27.7.4 Companies News and Developments
- 27.7.5 Certifications
- 27.8 Alkermes
- 27.8.1 Financial Analysis
- 27.8.2 Product Portfolio
- 27.8.3 Demographic Reach and Achievements
- 27.8.4 Companies News and Developments
- 27.8.5 Certifications
- 28 Alcohol Use Disorder Market - Distribution Model (Additional Insight)
- 28.1 Overview
- 28.2 Potential Distributors
- 28.3 Key Parameters for Distribution Partner Assessment
- 29 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 30 Payment Methods (Additional Insight)
- 30.1 Government Funded
- 30.2 Private Insurance
- 30.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
